Q3 2016 Earnings Estimate for Sarepta Therapeutics Inc. (SRPT) Issued By Jefferies Group
Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Stock analysts at Jefferies Group upped their Q3 2016 earnings estimates for shares of Sarepta Therapeutics in a note issued to investors on Sunday. Jefferies Group analyst G. Wang now anticipates that the brokerage will post earnings of ($1.33) per share for the quarter, up from their prior forecast of ($1.38). Jefferies Group currently has a “Hold” rating and a $58.00 price target on the stock. Jefferies Group also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.16) EPS, FY2016 earnings at ($5.13) EPS and FY2017 earnings at $0.35 EPS.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm earned ($0.87) earnings per share.
A number of other equities analysts have also commented on the company. Cowen and Company reissued a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, August 15th. Janney Montgomery Scott raised Sarepta Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $30.00 to $65.00 in a research note on Monday, September 19th. William Blair reissued an “outperform” rating and set a $88.00 price target on shares of Sarepta Therapeutics in a research note on Sunday. Robert W. Baird reissued an “outperform” rating and set a $23.00 price target on shares of Sarepta Therapeutics in a research note on Monday, July 18th. Finally, JMP Securities reaffirmed an “underperform” rating and issued a $10.00 price objective on shares of Sarepta Therapeutics in a research note on Sunday, July 24th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $54.86.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 1.46% during trading on Wednesday, reaching $62.38. The company’s stock had a trading volume of 736,090 shares. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The company has a 50 day moving average of $37.94 and a 200-day moving average of $24.60. The stock’s market cap is $2.99 billion.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 24,352 shares of the firm’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,217,600.00. Following the completion of the sale, the chief executive officer now directly owns 89,983 shares of the company’s stock, valued at approximately $4,499,150. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.
Several hedge funds have recently bought and sold shares of SRPT. Teacher Retirement System of Texas boosted its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. acquired a new stake in Sarepta Therapeutics during the second quarter worth $154,000. Quantitative Systematic Strategies LLC acquired a new stake in Sarepta Therapeutics during the second quarter worth $211,000. BNP Paribas Arbitrage SA boosted its stake in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares during the last quarter. Finally, National Planning Corp boosted its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the last quarter. 65.29% of the stock is owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.